Latest News

view more

Podcasts

view more

Webinars

  • The Promise of Epigenetics in Early Stage Drug Discovery
    Epigenetic targets are exciting to drug discovery scientists because they hold great potential across a wide spectrum of therapeutic areas. The field of epigenetics focuses on the investigation of enzymes that alter gene expression through modification of their target substrates, usually through the addition or removal of methyl or acetyl groups. High-throughput assays to identify agents capable of modifying the action of such enzyme targets has, in the past, proven to be challenging due to the relatively small molecular alterations in addition to the possibility of sequential modifications, leading to multiple end products. As such, high-throughput bioassays that allow the direct, concurrent quantification of multiple modification states are attractive. The RapidFire platform enables high-throughput mass spectrometric analysis of native molecules from in vitro reactions by performing on-line desalting in seconds, as opposed to HPLC, which requires minutes. Moreover, the RapidFire system can be connected to any mass spectrometer providing unparalleled versatility in reaction detection.
  • Integrated Quant / Qual for In-vivo Discovery Bioanalysis using Hybrid Quadrupole-Time-of-Flight Mass Spectrometry
    Ultra high performance liquid chromatography (UHPLC) coupled with orthogonal acceleration hybrid quadrupole-time-of-flight (QqTOF) mass spectrometry is an emerging technique offering new strategies for the efficient screening of new chemical entities (NCE) and related molecules at the early discovery stage within the pharmaceutical industry.
  • Drug Delivery: enabling technology for discovery and development
    The integration of pharmacodynamic and pharmacokinetic parameters in non clinical pharmacology studies is a key aspect in drug discovery for efficacy and safety assessment, in the particular for the translation from the non clinical to the clinical field. Modeling the profile of plasma exposure achieved with the intended therapeutic route often requires the use of intravenous infusion. In addition, in most cases infusion parameters (infusion rate, volume, duration and sequences) need to be customized to achieve the appropriate pattern of plasma drug exposure. When pharmacodynamic parameters are recorded by telemetry, the use of implantable pumps rather than external pumps is necessary to preserve the improvement in physiological data recording offered by telemetry.
  • Part 2: How has HR-MS technology fundamentally changed the way we study drug biotransformation and disposition?
    AB SCIEX is proud to present the 2nd installment of a Global 4-Part Live Webinar Series exploring novel and dynamic workflows for Metabolite Identification & Drug Metabolism solutions as it pertains to the 4 main stages of the drug discovery and development paradigm, Lead Discovery, Late Stage Discovery, Early Development and Late Stage Development. Part 2 of this webinar series will focus on how HRMS technology has fundamentally changed the way metabolite biotransformations are investigated in Lead Discovery.
view more

Features

view more

Downloads

  • Pharmaceutical strategies in the emerging era of antibody-based biotherapeutics for the treatment of cancers overexpressing MET receptor tyrosine kinase
    Cancerous MET overexpression is a common pathological feature manifested by genetic, molecular, and cellular abnormalities. Conventional therapeutic antibodies targeting MET, under clinical trials for almost 10 years, have made little progress with various setbacks. Novel biotherapeutics, such as bispecific antibodies, antibody-drug conjugates, and their combination, are under anti-MET clinical trials. Amivantamab, a MET/EGFR bispecific antibody, has been granted the Breakthrough Therapy Designation status for treatment of advanced NSCLC. An emerging era of antibody-based biotherapeutics for treatment of cancer overexpressing MET is in the horizon.
  • The political economics of cancer drug discovery and pricing
    In highly politicised and heavily regulated markets for new anticancer drugs, the long-term value of extending life and reducing illness-related distress and disability is at risk of being underestimated: the fundamental goal of pharmaceutical price regulation should be to help assure universal access to continuously improving treatment
  • From patent to patient: analysing access to innovative cancer drugs
    Analysis of EMA-licensed cancer drugs finds that authorisations are increasing, but with low numbers in cancers with poorest outcomes, increased time to license new drugs, and evidence that highly innovative treatments are not sufficiently prioritised
  • Drug Discovery for Epigenetics Targets
    Epigenetic changes modify genetic information without altering the DNA sequence. Epigenetics related proteins are classified into readers, writers and erasers Dysregulation of the epigenome is associated with a number of diseases. Screening and rational design have been successfully applied to epigenetic targets
  • Epigenetics and therapeutic targets in gastrointestinal malignancies
    Discusses the epigenetics in gastrointestinal (GI) cancers Explore the metastatic role(s) of epigenetics in GI cancers. Present epigenetics as biomarkers for the diagnosis and monitoring of GI cancers. Epigenetics as therapeutic solutions for GI cancers
view more

25 Hottest Articles

view more